A new ultrasound measure may spot At-Risk babies in High-Blood-Pressure pregnancies

NCT ID NCT07795320

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

Researchers at Assiut University are testing whether a new ultrasound measurement, the Amniotic-Umbilical-to-Cerebral Ratio (AUCR), can predict complications in newborns of women with hypertensive disorders of pregnancy. They will compare AUCR with the traditional Cerebroplacental Ratio (CPR) in 130 women with a singleton pregnancy at 32 weeks or later. The main goal is to see which ratio better identifies babies who need neonatal intensive care shortly after birth. If AUCR proves more accurate, it could help doctors plan deliveries and newborn care more effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultrasound-based measurement of the Amniotic-Umbilical-to-Cerebral Ratio (AUCR) compared with the Cerebroplacental Ratio (CPR)
What this could lead to
If AUCR proves more accurate than CPR, doctors could better identify which babies of mothers with high blood pressure need intensive care, allowing earlier and more targeted monitoring.
What could go wrong
This is a single-center study with 130 participants, and the new ratio may not outperform the standard one. Ultrasound measurements can vary between operators, and results may not apply to all pregnancies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

pregnant women with hypertensive disorder

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-40 years, inclusive. * Singleton viable pregnancy. * Gestational age ≥32 weeks. * Pregnancy complicated by a hypertensive disorder. * Women who provide written informed consent. Exclusion Criteria: * Multiple gestation. * Fetuses with known chromosomal or major congenital anomalies. * Maternal diseases likely to independently affect fetal circulation or perinatal outcome, such as significant cardiac disease or other major systemic diseases. * Inability to complete the required follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension disorders in pregnancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.